[Therapy with XXXX inhibitors in chronic @entity712 and limited kidney function].

@entity1 @entity4688 @entity712 @entity1289 @entity101 @entity117 @entity3371 @entity3593
Renal function in 31 @entity1 with mild to moderate @entity712 (NYHA Classes II-III) was studied before and during treatment with @entity1289 -inhibitors. Maximal treatment doses were based on randomization: @entity3371 3 x 12.5 mg or @entity3593 or @entity4688 , both 1 x 10 mg. Before therapy and at the end of titration phase (after 6 days) glomerular filtration rate and renal blood flow were determined from inulin and PAH clearance (steady-state method). In the total study group the median arterial pressure significantly decreased from 94 mmHg to 84 mmHg (p < 0.01), whereas glomerular filtration rate was only moderately, however, significantly reduced from 103 ml/min to 97 ml/min (median values, p < 0.01). Renal blood flow, however, increased from 372 ml/min to 403 ml/min (p < 0.01). Changes in glomerular filtration rate (GFRd) were significantly dependent on those of renal blood flow (GFRd = 0.07 RPFd - 9.2; p < 0.05). All three @entity1289 -inhibitors showed similar changes in glomerular filtration rate and renal blood flow. Ten of the @entity1 had additionally received cyclooxygenase inhibitors. With respect to severity of @entity712 and renal function these @entity1 did not differ from the remaining 21 @entity1 of the group. In both groups, a decrease of glomerular filtration rate was found, however, in those @entity1 who had received @entity117 there was no @entity101 . CONCLUSION: A small, however significant decrease of glomerular filtration rate is already seen in @entity1 with mild to moderate @entity712 treated with @entity1289 -inhibitors. Increase of renal blood flow counteracts the decrease of glomerular filtration rate. During concomitant application of @entity117 the @entity101 remains absent.
